Ads
related to: parkinson's disease gba1 variant cancerbostonscientific.com has been visited by 10K+ users in the past month
amazon.com has been visited by 1M+ users in the past month
Search results
Results From The WOW.Com Content Network
An existing cancer drug has shown promise in halting Parkinson's disease progression in mouse models. More research is needed to confirm these findings.
Parkinson's disease (PD), or simply Parkinson's, is a neurodegenerative disease primarily of the central nervous system, affecting both motor and non-motor systems. Symptoms typically develop gradually, with non-motor issues becoming more prevalent as the disease progresses.
Parkinson's disease (PD), the second most common neurodegenerative disease after Alzheimer's disease, affects 1% of people over 60 years of age. [1] [2] [3] In the past three decades, the number of PD cases has doubled globally from 2.5 million in 1990 to 6.1 million in 2016. [4] [5] As of 2022, there are ~10 million PD cases globally. [6]
Parkinsonism is a clinical syndrome characterized by the four motor symptoms found in Parkinson's disease: tremor, bradykinesia (slowed movements), rigidity, and postural instability. [ 1 ] [ 2 ] Parkinsonism gait problems can lead to falls and serious physical injuries.
Children’s developing neurological systems and rapidly growing cells are far more susceptible to toxic chemicals than those of adults; childhood leukemia is 35% more prevalent now than 30 years ago.
"for identifying GBA1 and LRRK2 as risk genes for Parkinson's disease, implicating autophagy and lysosomal biology as critical contributors to the pathogenesis of the disease." Hertie Institute for Clinical Brain Research, University of Tübingen and German Center for Neurodegenerative Diseases: Ellen Sidransky United States